New inhaled powder for COPD heads into first human tests

NCT ID NCT07567872

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-stage study tests an inhaled powder called HRS-9821 in healthy volunteers and people with COPD. The main goal is to check safety and how the body handles the drug. About 48 participants will receive either the drug or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-9821 powder for inhalation
What this could lead to: If successful, this could lead to a new inhaled treatment option for COPD that helps control the disease.
What could go wrong: This is a very early Phase 1 trial with only 48 participants, focused on safety. It is too small and early to know if the drug will work or be safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.